AI주식인사이트AI Stock Insight
C

에이프로젠바이오로직스

003060KOSPI의약품 제조업

52.4 / 100

Reference Date: 2026-06-10

Financial Score11.5 / 40
News Sentiment16.9 / 25
Momentum12.0 / 20
Disclosure12.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Surged 939.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Aprogen BioLogics operates two business segments: a pharmaceutical division producing synthetic drugs and a biopharmaceutical division manufacturing biologics. Its Cheongju-based Osong facility boasts world-class antibody production capacity, capable of producing over 2.8 million liters of culture media annually. The affiliated company Aprogen Pharma focuses on drug distribution, though the group reported an operating loss as of 2023.

Number of Employees

445people

Average Salary

47.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 11.934.0Point
PBR
0.14Industry Average 0.897.0Point

Half of industry avg (excellent)

ROE
-51.29Industry Average 4.010.0Point

Well below industry avg

Debt Ratio
28.93Industry Average 12.430.0Point

2.3x industry avg (risky)

Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼7.1% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼3.1% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -35.2% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 67.5

Detailed Momentum

52-week position5.0Point

52w mid range (48%)

Current 2,610Won52-week high 5,10052-week low 235
1-month return6.0Point

1m +939.84% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

10 totalPositive 1Neutral 9Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-06-05
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05
  • Neutral[기재정정]주요사항보고서(전환사채권발행결정)2026-06-02
  • Neutral기업지배구조보고서공시2026-06-01
  • Positive유상증자또는주식관련사채등의발행결과(자율공시)2026-05-29